Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia
Pharmacology and Toxicity of Erwinia Asparaginase (Erwinase?; Crisantaspase; IND 290) Following Allergy to PEG-Asparaginase in Treatment of Children With Acute Lymphoblastic Leukemia (ALL)
Sponsor: Children's Oncology Group
This NA trial investigates Adult Acute Lymphoblastic Leukemia and Childhood Acute Lymphoblastic Leukemia and is currently completed. Children's Oncology Group leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Aug 2019 — Jan 2021 [monthly]
Completed NA
▶ Show 4 earlier versions
-
Jul 2019 — Aug 2019 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jun 2018 — Jul 2019 [monthly]
Unknown Status NA
-
Apr 2018 — Jun 2018 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
First recorded
Feb 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Oncology Group
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .